Troluce Capital Advisors LLC Biomarin Pharmaceutical Inc Transaction History
Troluce Capital Advisors LLC
- $826 Million
- Q2 2024
A detailed history of Troluce Capital Advisors LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Troluce Capital Advisors LLC holds 71,600 shares of BMRN stock, worth $6.07 Million. This represents 0.71% of its overall portfolio holdings.
Number of Shares
71,600Holding current value
$6.07 Million% of portfolio
0.71%Shares
1 transactions
Others Institutions Holding BMRN
# of Institutions
631Shares Held
185MCall Options Held
1.63MPut Options Held
1.2M-
Black Rock Inc. New York, NY22.7MShares$1.93 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.61 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA18.8MShares$1.59 Billion1.14% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$1.18 Billion0.72% of portfolio
-
Capital Research Global Investors Los Angeles, CA9.69MShares$822 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $15.8B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...